Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 5, 2004, Pages 23-25

  Conti, Matteo ^a   De Giorgi, U ^b   Tazzari, V ^a   Bezzi, F ^a   Baccini, C ^a  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Cisplatin; Clinical pharmacology; Intraperitoneal chemotherapy

Indexed keywords

CISPLATIN;

AREA UNDER THE CURVE; ASCITES; BLOOD TOXICITY; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TISSUE LEVEL; HUMAN; KIDNEY TUBULE DAMAGE; NEPHROTOXICITY; NEUROTOXICITY; OVARY CARCINOMA; PERITONEUM TUMOR;

EID: 11144239617     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1120009x.2004.11782377     Document Type: Conference Paper

References (10)

1. Hofstra LS, de Vries EGE, Mulder NH, Willemse PHB. Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev 2000;26:133-43. And references therein.
2. Tsujitani S, Fukuda K, Salto H, et al. The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer. Surgery 2002; 131(1 Suppl):S98-104.
3. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335(26): 1950-5.
4. Topuz E, Eralp Y, Saglam S, et al. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecologic Oncology 2004; 92: 147-151. And references therein.
5. Goel R, Cleary S, Horton C, et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 1989; 81; 1552-60.
6. Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22: 1329-36.
7. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989; 49; 3380-4.
8. Zeamari S, Floot B, van der Vange N, Stewart FA.Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Anticancer Res. 2003; 23(2B): 1643-8.
9. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34: 148-54.
10. Willemse PHB, de Vries EGE. Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility? Drug Resistance Updates 2003; 6: 165-167.